Target intelligence / Profile preview

Epstein-Barr virus nuclear antigen 1 peptide-human leukocyte antigen complexes (EBNA1-peptide-HLA complexes)

Target
EBNA1-peptide-HLA complexes
Molecular classification
Receptor, Other
01

Overview

Epstein-Barr virus nuclear antigen 1 (EBNA1) peptide-human leukocyte antigen (HLA) complexes represent a class of therapeutic targets consisting of processed peptides from the intracellular EBNA1 protein presented on the cell surface by HLA class I or class II molecules. EBNA1 is a multifunctional viral protein essential for the replication, partitioning, and maintenance of the EBV episome during latent infection, and it is expressed in all EBV-associated malignancies, including nasopharyngeal carcinoma, Hodgkin lymphoma, Burkitt's lymphoma, and EBV-positive gastric cancer. Because EBNA1 is an intracellular protein, it cannot be targeted by conventional monoclonal antibodies; however, its degradation products are presented as peptide-HLA complexes on the cell surface, making them accessible to T-cell receptor (TCR)-engineered T cells (TCR-T) and TCR-like monoclonal antibodies. Therapies targeting these complexes, such as the TCR-T cell product YT-E001 and TCR-like antibodies like E1, aim to selectively eliminate EBV-infected or malignant cells while sparing healthy tissues. A major therapeutic challenge and safety concern is the potential for cross-reactivity and molecular mimicry, as EBNA1-derived peptides have been implicated in autoimmune diseases like multiple sclerosis through cross-reactivity with central nervous system antigens such as GlialCAM.

Other names
EBNA1-derived peptide-HLA complexesEBNA1 peptide-MHC complexesEBNA1 pMHC complexesEpstein-Barr nuclear antigen 1 peptide-HLA complexesEBNA1-derived peptide-MHC complexes
02

Mechanism of action

TCR-T cell therapy or TCR-like monoclonal antibodies bind to the EBNA1-derived peptide-HLA complexes on the surface of EBV-infected or malignant cells, triggering T-cell activation or antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) to selectively destroy the target cells.

03

Biological functions

Immune responseOther
04

Disease associations

CancerInfectionNeurodegenerative diseaseOther
05

Safety considerations

Cross-reactivity with self-antigens (molecular mimicry, e.g., GlialCAM in multiple sclerosis)Cytokine release syndrome (CRS)Immune effector cell-associated neurotoxicity syndrome (ICANS)On-target, off-tumor toxicity
06

Interacting drugs

1 more in the full profile.

07

Biomarkers

EBV-positivityEBNA1 expressionHLA-A*02:01 expressionHLA-A*24:02 expressionHLA-A*11:01 expression

Beyond the preview

Go deeper on Epstein-Barr virus nuclear antigen 1 peptide-human leukocyte antigen complexes (EBNA1-peptide-HLA complexes).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Epstein-Barr virus nuclear antigen 1 peptide-human leukocyte antigen complexes (EBNA1-peptide-HLA complexes).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call